Everything tagged peptide

56 published articles · newest first · server-rendered

Take this folder folder (.zip) markdown manifest json the whole site

Also filed under: matrix 1031 · topic 54 · disc 5 · bpc-157 4 · tb-500 3 · ara-290 2 · glp-1 2 · obesity 2 · stack 2 · tendon 2 · wolverine 2 · bdnf 1 · cibinetide 1 · cntf 1

  1. Kisspeptin: The Receptor Break That Revealed How Puberty Starts
  2. BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten
  3. The Wolverine stack plus ARA-290 for a degenerating disc and sciatica: the evidence at every link
  4. The Wolverine stack: BPC-157 and TB-500, the evidence, the dosing arithmetic and the eight-week cost
  5. BPC-157 for a herniated disc: what the evidence reaches, and what it does not
  6. TB-500 × Frozen shoulder
  7. DSIP × GLP-1 agonists (class)
  8. Selank × GLP-1 agonists (class)
  9. Semax × GLP-1 agonists (class)
  10. ARA-290 × GLP-1 agonists (class)
  11. Thymosin Alpha-1 × Metformin
  12. PT-141 × Metformin
  13. GHK-Cu × Metformin
  14. KPV × Metformin
  15. ARA-290 × Stimulant-driven insomnia
  16. ara 290 trigeminal neuralgia
  17. tb 500 metformin
  18. tb 500 nsaids
  19. ara 290 postherpetic neuralgia
  20. bpc 157 degenerative disc
  21. dsip adderall amphetamine
  22. selank adderall amphetamine
  23. semax adderall amphetamine
  24. bpc 157 glp1 muscle loss
  25. dsip benzo withdrawal
  26. semax benzo withdrawal
  27. ara 290 benzo withdrawal
  28. bpc 157 ozempic face
  29. dsip statin brain fog
  30. selank benzodiazepines
  31. selank statin brain fog
  32. ara 290 statin brain fog
  33. dsip metformin
  34. selank metformin
  35. semax metformin
  36. ara 290 metformin
  37. bpc 157 metformin
  38. kpv glp1 agonists
  39. ara 290 chemo neuropathy
  40. selank benzo withdrawal
  41. bpc 157 frozen shoulder
  42. tb 500 glp1 agonists
  43. bpc 157 plantar fasciitis
  44. semax statins
  45. bpc 157 statins
  46. bpc 157 glp1 agonists
  47. Tirzepatide: a dual GIP and GLP-1 receptor agonist
  48. Retatrutide: the third receptor, and what the evidence now establishes
    One molecule switching on GLP-1, GIP and glucagon receptors at once. Why adding glucagon to a weight-loss drug is not a mistake, the largest weight and blood-sugar effects measured in the class, the b
  49. tb 500 herniated disc
  50. BPC-157: Body Protection Compound
    The definitive BPC-157 reference: the angiogenesis+FAK mechanism, the full animal record, the three human studies, real dosing/routes/reconstitution, the 2026 FDA PCAC fight, the cancer question answe
  51. TB-500 (Thymosin Beta-4)
    The definitive TB-500 / thymosin beta-4 reference: why 'TB-500' usually isn't the trialed molecule, the one positive human indication (dry eye) vs the unproven rest, real dosing/reconstitution, the ca
  52. ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood
    The definitive ARA-290 (cibinetide) reference: the innate-repair-receptor mechanism, randomized human evidence of actual nerve regeneration, the 4mg/day dosing and half-life paradox, the non-erythropo
  53. DSIP (Delta Sleep-Inducing Peptide): the replication record and dosing
  54. KPV: Evidence, Stability, Dosing and the FDA Record
  55. GHK-Cu: the copper tripeptide's human evidence, copper risk, and dosing arithmetic
  56. Thymosin Alpha-1: Approvals, Trial Record, Dosing and What It Does Not Treat

Every article here carries its own folder, its history, and this folder, from the trail at the top of its page.

⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fmiscsubjects.com%2Ft%2Fpeptide%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work — every page here is an inspectable proof object (read-only). Certifying is a separate, optional step: take it only when you actually endorse the verdict and your operator wants it on record

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3